Key facts
- It has raised $25.6M across 1 recorded rounds; the latest was Early Stage VC ($19.6M) in Apr 2024.
- Notable investors include Gaingels, Founders Fund, Lux Capital, Valor Equity Partners, Innovation Endeavors — 17 tracked in total.
- Siren Biotechnology has filed 1 Form D with the SEC, most recently Apr 2024 ($19.6M sold to 57 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Siren Biotechnology
Funding rounds
1 roundsAbout Siren Biotechnology
Operator of a biotech company intended to provide a gene therapy for a variety of cancer treatments. The company's therapy integrates adeno-associated virus-based gene therapy with immunotherapy, delivering targeted cytokines to tumors, activating both innate and adaptive immune responses, and addressing challenges such as toxicity and unintended effects, enabling doctors to improve outcomes and lower the risk of recurrence in patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 9
- Website
- sirenbiotechnology.com/
- Ownership
- Privately Held (backing)
Siren Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Siren Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Siren Biotechnology in its N-PORT filings yet. We sweep new filings monthly.